These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7658577)

  • 1. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy.
    Edelstein RA; Bauer SB; Kelly MD; Darbey MM; Peters CA; Atala A; Mandell J; Colodny AH; Retik AB
    J Urol; 1995 Oct; 154(4):1500-4. PubMed ID: 7658577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration.
    Kasabian NG; Bauer SB; Dyro FM; Colodny AH; Mandell J; Retik AB
    Am J Dis Child; 1992 Jul; 146(7):840-3. PubMed ID: 1496955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele.
    Kaefer M; Pabby A; Kelly M; Darbey M; Bauer SB
    J Urol; 1999 Sep; 162(3 Pt 2):1068-71. PubMed ID: 10458433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of children with myelodysplasia: urological alternatives.
    Klose AG; Sackett CK; Mesrobian HG
    J Urol; 1990 Dec; 144(6):1446-9. PubMed ID: 2231940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup.
    Hopps CV; Kropp KA
    J Urol; 2003 Jan; 169(1):305-8. PubMed ID: 12478177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clean, intermittent catheterization of infants with neurogenic bladder.
    Joseph DB; Bauer SB; Colodny AH; Mandell J; Retik AB
    Pediatrics; 1989 Jul; 84(1):78-82. PubMed ID: 2740179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relevance of urethral resistance in children with myelodysplasia: its impact on upper urinary tract deterioration and the outcome of conservative management.
    Tanaka H; Kakizaki H; Kobayashi S; Shibata T; Ameda K; Koyanagi T
    J Urol; 1999 Mar; 161(3):929-32. PubMed ID: 10022727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoscopic treatment of vesicoureteral reflux in patients with myelodysplasia.
    Yokoyama O; Ishiura Y; Seto C; Uchibayashi T; Ohkawa M
    J Urol; 1996 Jun; 155(6):1882-6. PubMed ID: 8618279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of urodynamic testing in the management of neonates with myelodysplasia: a prospective study.
    Sidi AA; Dykstra DD; Gonzalez R
    J Urol; 1986 Jan; 135(1):90-3. PubMed ID: 3941475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurogenic bladder dysfunction due to myelomeningocele: neonatal versus childhood treatment.
    Wu HY; Baskin LS; Kogan BA
    J Urol; 1997 Jun; 157(6):2295-7. PubMed ID: 9146656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The urodynamic profile of myelodysplasia in childhood with spinal closure during gestation.
    Holzbeierlein J; Pope JC IV; Adams MC; Bruner J; Tulipan N; Brock JW
    J Urol; 2000 Oct; 164(4):1336-9. PubMed ID: 10992409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urologic aspects of myelodysplasias in children].
    Urbanowicz W
    Przegl Lek; 1998; 55(4):211-6. PubMed ID: 9656750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urethral dilation in the management of urological complications of myelodysplasia.
    Wang SC; McGuire EJ; Bloom DA
    J Urol; 1989 Oct; 142(4):1054-5. PubMed ID: 2795730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for febrile urinary tract infection in children with myelodysplasia treated by clean intermittent catheterization.
    Seki N; Masuda K; Kinukawa N; Senoh K; Naito S
    Int J Urol; 2004 Nov; 11(11):973-7. PubMed ID: 15509200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome analysis of vesicoureteral reflux in children with myelodysplasia.
    Agarwal SK; Khoury AE; Abramson RP; Churchill BM; Argiropoulos G; McLorie GA
    J Urol; 1997 Mar; 157(3):980-2. PubMed ID: 9072629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasonographic measurement of bladder wall thickness as a risk factor for upper urinary tract deterioration in children with myelodysplasia.
    Tanaka H; Matsuda M; Moriya K; Mitsui T; Kitta T; Nonomura K
    J Urol; 2008 Jul; 180(1):312-6; discussion 316. PubMed ID: 18499168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of risk factors for upper urinary tract deterioration in patients with myelodysplasia.
    Seki N; Akazawa K; Senoh K; Kubo S; Tsunoda T; Kimoto Y; Naito S
    BJU Int; 1999 Oct; 84(6):679-82. PubMed ID: 10510115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The urological evaluation and management of patients with myelodysplasia.
    Webster GD; el-Mahrouky A; Stone AR; Zakrzewski C
    Br J Urol; 1986 Jun; 58(3):261-5. PubMed ID: 3719246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of myelomeningocele.
    Kaplan WE
    Urol Clin North Am; 1985 Feb; 12(1):93-101. PubMed ID: 3883627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The urological screening of children with myelodysplasia].
    Nikolaev VV; Braev AT
    Zh Vopr Neirokhir Im N N Burdenko; 2000; (1):27-9; discussion 29-30. PubMed ID: 10738762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.